Sirpiglenastat

Research use only, not for human use.

Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.

Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.

Sirpiglenastat (DRP-104) treatment shows broad immune cell modulation effects including increased T, NK, and macrophages. Sirpiglenastat decreases pro-tumorigenic cytokines such as VEGF and KC (IL-8).

CT26 bearing mice treated with Sirpiglenastat (DRP-104) (0.5 mg/kg; s.c.; once a day; for 5 days) shows tumor growth inhibition at day 12 of 90%. Median survival days are 36 days. Sirpiglenastat (0.5 mg/kg; s.c) treatment significantly inhibits tumor growth in the H22 model.Animal Model:CT26 bearing mice Dosage:0.5 mg/kg Administration:s.c.; once a day; for 5 days Result:Showed tumor growth inhibition in mice.

——

Others

Other Targets

Glutaminase

——

——

2079939-05-0

441.48

C22H27N5O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (226.51 mM; Ultrasonic )

C([C@@H](C(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)NC(C)=O)C=1C=2C(NC1)=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years